Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Phase III study of NC-6004 in pancreatic cancer concludes

Nov. 30, 2020

DAY-101 well tolerated, shows antitumor activity in patients with recurrent low-grade glioma

Nov. 30, 2020

New EZH2 inhibitors synthesized at PharmaBlock Sciences

Nov. 30, 2020

Qilu Regor Therapeutics presents new CDK inhibitors

Nov. 30, 2020

New CD134 agonists identified at Bicycle Therapeutics

Nov. 30, 2020

Cabometyx approved in Japan for unresectable previously treated HCC

Nov. 30, 2020

Golden Biotechnology reports phase IIa results with antroquinonol in relapsed AML

Nov. 27, 2020

Constellation Pharmaceuticals initiates phase III MANIFEST-2 study of CPI-0610

Nov. 27, 2020

Chaser Therapeutics identifies new USP28 and USP25 inhibitors

Nov. 27, 2020

TYK Medicines divulges protein kinase inhibitors

Nov. 27, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...